Navidea Biopharmaceuticals Inc Net debt/EBITDA
What is the Net debt/EBITDA of Navidea Biopharmaceuticals Inc?
The Net debt/EBITDA of Navidea Biopharmaceuticals Inc is 0.38
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NYSEMKT compared to Navidea Biopharmaceuticals Inc
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Companies with net debt/ebitda similar to Navidea Biopharmaceuticals Inc
- Kühne + Nagel International AG has Net debt/EBITDA of 0.37
- Enphase has Net debt/EBITDA of 0.38
- Global Technologies has Net debt/EBITDA of 0.38
- RoodMicrotec N.V has Net debt/EBITDA of 0.38
- VentriPoint Diagnostics has Net debt/EBITDA of 0.38
- AM Resources has Net debt/EBITDA of 0.38
- Navidea Biopharmaceuticals Inc has Net debt/EBITDA of 0.38
- Caledonia Investments Plc has Net debt/EBITDA of 0.38
- Tymlez has Net debt/EBITDA of 0.38
- Synovus has Net debt/EBITDA of 0.39
- Eskay Mining has Net debt/EBITDA of 0.39
- Foxconn Interconnect Technology has Net debt/EBITDA of 0.39
- DermTech has Net debt/EBITDA of 0.39